Beukelman, Timothy G., MD, MSCE

mug-08-2007

Associate Professor, Division of Pediatric Rheumatology
Department of Pediatrics


Secondary Appointment: Division of Clinical Immunology & Rheumatology

Address: 

Children's Park Place, Suite 210
1601 4th Avenue South
Birmingham, AL 35233-1711

 

Telephone:(205) 996-9191
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Education

 

BS, University of Illinois, Urbana-Champaign, IL, 1997
MD, Washington University, Saint Louis, MO, 2001
Intern (Pediatrics): Cincinnati Children’s Hospital Medical Center, OH, 2002
Resident (Pediatrics): Cincinnati Children’s Hospital Medical Center, OH, 2004
Fellow (Pediatric Rheumatology):The Children’s Hospital of Philadelphia, PA, 2007
M.S.C.E., University of Pennsylvania, Philadelphia, PA, 2008

 

Awards and Honors

 

2013                ACR/EULAR International Academic Rheumatology Exchange, Early Career Investigator Delegate

2007                University of Alabama Health Services Foundation General Endowment Fund Scholar Award

2005-2006       Ruth L. Kirschstein National Research Service Award (NRSA), National Institutes of Health

 

Research Description

 

Optimizing the treatment of juvenile idiopathic arthritis using various clinical research methods including retrospective analysis of observational data, prospective observational data collection and analysis, decision analysis, and clinical trials.

 

Selected Publications

 

Beukelman T, Ringold S, Davis TE, Morgan DeWitt E, Pelajo CF, Weiss PF, Kimura Y. Disease modifying anti-rheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J Rheumatol 2012; 39:1867-74.

Stoll ML, Sharpe T, Beukelman T, Good J, Young D, Cron RQ. Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. J Rheumatol 2012; 39:1880-7.

Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:2773-80.

Curtis JR, Xie F, Chen L, Munter P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E. Use of a disease risk score to compare serious infections associated with anti-TNF therapy among high versus lower risk rheumatoid arthritis patients. Arthritis Care Res 2012.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus H, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64:625-39.

Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64:1263-7.

DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012; 64:1001-10.

Donnithorne KJ, Cron RQ, Beukelman T. Inactive disease status following initiation of TNFα inhibitor therapy in a heterogeneous cohort of children with juvenile idiopathic arthritis: Enthesitis related arthritis predicts persistent active disease. J Rheumatol 2011; 38:2675-81.

Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331-9.

Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, Solomon DH, Griffin MR, Ouellet-Hellstom R, Beukelman T, Grijalva CG, Haynes K, Kuriya B, Lii J, Mitchel E Patkar NM, Rassen J, Winthrop KL, Nourjah P, Saag KG. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf 2011; 20:1199-209.

Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag K, Spettell C, McMahan RM, Fernandes J, Winthrop K, Delzell E. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biologic agents. Ann Rheum Dis 2011; 70:1401-6.

Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63:465-82.

Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, Morgan DeWitt E, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care. A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res 2011; 63:10-16.

Beukelman T, Saag KG, Curtis JR, Kilgore ML, Pisu M. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 2010; 21:1573-84.

Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg J, Kavanaugh A, Reed G, Strand V,  Kremer JM. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69:43-7.

Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis. Arthritis Rheum 2008; 59:1580-88.

Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. Clin Exp Rheumatol 2008; 26:700-3.

Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. J Rheumatol 2007; 34:1918-24.

Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34:1133-8.

Beukelman T, Arabshahi B, Cahill AM, Kaye RD, Cron RQ. Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. J Rheumatol 2006; 33:2330-6.

Beukelman T, Cron RQ. JIA-associated growth failure and exogenous growth hormone therapy. Pediatr Rheumatol Online J 2005; 3:99-108.

SOM Epilogue Menu